Norway· NO-ID_3090129E-CCAA-4ECE-93D5-A052CD596F48
Asacol
A mesalazine product containing mesalazine, registered in Norway by Abacus Medicine A/S. The same ATC class is registered in 17 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Mesalazine is registered in 17 of 19 countries.
Countries holding a registration under ATC A07EC02 (mesalazine), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Mesalazine · ATC A07EC02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of mesalazine costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), the median price runs from $1.00 in Italy to $2.13 in Switzerland — a ×2.1 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mesalazine · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.13
- FR France$1.06
- IT Italy$1.00
The record
At a glance
FEST (Norway)- Active substance
- Mesalazine
- Manufacturer
- Abacus Medicine A/S
- Country
- Norway (NO)
- ATC code
- A07EC02
- ATC class
- Mesalazine
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- October 2, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_3090129E-CCAA-4ECE-93D5-A052CD596F48
- no_varenummer43542860NOK 1045
- gtin5712440022188
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
333 interactions on record for mesalazine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mesalazine · interactions on record
333 records
- 15 severe
- 95 moderate
- 223 info
Most severe, free to view
- CidofovirJ05AB12severe
- Humane Immunglobuline, unspezifisch, extravaskulärJ06BA01severe
- Humane Immunglobuline, unspezifisch, intravaskulärJ06BA02severe
- SirolimusL01EG04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A07EC02
Mesalazine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/51e02d3b-4e99-4689-9e3f-a81df0c002cc GET /v1/drugs/51e02d3b-4e99-4689-9e3f-a81df0c002cc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett med modifisert frisetting",
"source": "fest",
"status": "A",
"atc_name": "Mesalazin",
"merkevare_id": "ID_3090129E-CCAA-4ECE-93D5-A052CD596F48",
"name_form_strength": "Asacol tab modif frisetting 1600 mg",
"prescription_group": "C"
}See everything about mesalazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.